CAPSTONE HOLDING CORP (CAPS) Stock News
NASDAQ:CAPS - Nasdaq - US14068E2081 - Common Stock - Currency: USD
CAPS Latest News, Press Relases and Analysis
Capstone Holding Corp. Announces Exercise Of Secured Debt And Interest Conversion Option By Majority Shareholder, BP Peptides, LLC
ALSIP, IL / ACCESSWIRE / June 21, 2022 / Capstone Holding Corp. (OTCQB:CAPS) ("the Company")
Capstone Therapeutics Corp. Announces Results of Annual Meeting
ALSIP, IL / ACCESSWIRE / December 2, 2021 / Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company"): The Annual Meeting of Stockholders of Capstone Therapeutics Corp., a Delaware corporation, was held on Wednesday, December 1, 2021 at 11:00 p.m. (local time) at the offices of the Company, 5141 W 122nd Street Alsip, IL 60803, for the following purposes: (1) To elect two directors as Class III Directors to serve until the Annual Meeting of
Capstone Therapeutics Corp. Announces Transaction with Diamond Products Holdings, LLC
Capstone Subsidiary Issues Debt to Acquire Equity Interest in Operating Company ALSIP, IL / ACCESSWIRE / April 6, 2021 / On March 31, 2021, the Company, through its relationship with Brookstone Partners (New York), executed definitive documents and acquired a minority interest in a consumer products company, Diamond Products, LLC ("Diamond"), a sexual wellness holding company. The transaction is based on the following
Capstone Therapeutics Announces Operating Results for Fiscal 2020 - Including a Change in Its Deferred Tax Valuation Allowance
ALSIP, IL / ACCESSWIRE / March 31, 2021 / Capstone Therapeutics (OTCQB:CAPS) ("the Company") today filed its Annual Report for the year ended December 31, 2020 with the OTCQB at www.OTCIQ.com. Net income attributable to Capstone Therapeutics Corp. stockholders totaled $8.5 million or $107.59 per share. Net income attributable to Capstone Therapeutics Corp. stockholders included a Federal income tax benefit of $8.7 million or $109.48 per
Capstone Therapeutics Announces Results of Special Shareholder Meeting, and a License Transfer/Royalty Agreement and Exit from the Pharmaceutical Development Business
ALSIP, IL / ACCESSWIRE / February 18, 2021 / Capstone Therapeutics (OTCQB:CAPS) ("the Company") On February 5, 2021, the Company held a special shareholder meeting following notice and distribution of a proxy statement setting forth four proposals for shareholder vote. The meeting was held virtually by video conference due to Covid restrictions with the members of the Company's Board of Directors and a Computershare representative,
Capstone Therapeutics Announces Exercise of Secured Debt and Interest Conversion Option by BP Peptides, LLC and Change in Control
ALSIP, IL / ACCESSWIRE / December 28, 2020 / Capstone Therapeutics (OTCQB:CAPS) ("the Company"): EXERCISE OF SECURED DEBT AND INTEREST CONVERSION OPTION; ISSUANCE OF 24,900 SHARES OF THE COMPANY'S COMMON STOCK On December 21, 2020, BP Peptides, LLC ("Brookstone") exercised its right to convert $572,700 of accrued interest and secured debt into 24,900 shares of the Company's Common Stock (exercise price of